What does this research mean for the field?

Higher baseline body mass index (≥25 kg/m2) and elevated body fat percentage are associated with a lower risk of death in patients with solid tumors receiving PD-1/PD-L1 inhibitors. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine whether baseline body composition measured via bioelectrical impedance analysis is a prognostic factor for survival outcomes in patients with solid tumours receiving PD-1/PD-L1 inhibitors.

September 2, 2026Journal of Personalized MedicineOpen Access

Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1/PD-L1 Inhibitors: A Prospective Exploratory Study

View Full Paper

Ask AI

Bookmark

Authors

AMAngela Morell AMAlberto Morell AAAinhoa Aranguren

Discussion

Member takes

Overview

Prospective observational study reveals higher body mass index and fat percentage predict improved survival in solid tumor patients receiving PD-1/PD-L1 inhibitors, highlighting adiposity's...

Key Points

To determine whether baseline body composition measured via bioelectrical impedance analysis is a prognostic factor for survival outcomes in patients with solid tumours receiving PD-1/PD-L1 inhibitors.
Conducted a prospective, single-centre observational study in 80 patients (median age 67 years; 60% male) with solid tumours initiating PD-1/PD-L1 inhibitor therapy.
Assessed baseline body composition using multifrequency bioelectrical impedance analysis (BIA).
Evaluated overall survival, progression-free survival, and treatment-related adverse events using Kaplan–Meier curves and multivariable Cox regression models adjusted for tumour stage and metastatic status.
Baseline BMI ≥ 25 kg/m² was independently associated with a lower risk of death compared to BMI < 25 kg/m² (adjusted HR 0.286, 95% CI 0.087–0.941; p = 0.039).
Elevated body fat percentage independently predicted reduced mortality after adjusting for tumour stage and metastatic status (adjusted HR 0.289, 95% CI 0.087–0.963; p = 0.036).
Neither baseline BMI nor body fat percentage was significantly associated with the incidence of confirmed immune-related adverse events.

Cite This Study

Morell et al. (2026) studied this question.

synapsesocial.com/papers/6a97e28dc562ede874ec6ae9 https://doi.org/10.3390/jpm16090457

View Full Paper

Ask AI

Bookmark

September 2, 2026Journal of Personalized MedicineOpen Access

Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1/PD-L1 Inhibitors: A Prospective Exploratory Study

View Full Paper

Ask AI

Bookmark

Authors

AMAngela Morell AMAlberto Morell AAAinhoa Aranguren

Discussion

Member takes

Overview

Prospective observational study reveals higher body mass index and fat percentage predict improved survival in solid tumor patients receiving PD-1/PD-L1 inhibitors, highlighting adiposity's...

Key Points

To determine whether baseline body composition measured via bioelectrical impedance analysis is a prognostic factor for survival outcomes in patients with solid tumours receiving PD-1/PD-L1 inhibitors.
Conducted a prospective, single-centre observational study in 80 patients (median age 67 years; 60% male) with solid tumours initiating PD-1/PD-L1 inhibitor therapy.
Assessed baseline body composition using multifrequency bioelectrical impedance analysis (BIA).
Evaluated overall survival, progression-free survival, and treatment-related adverse events using Kaplan–Meier curves and multivariable Cox regression models adjusted for tumour stage and metastatic status.
Baseline BMI ≥ 25 kg/m² was independently associated with a lower risk of death compared to BMI < 25 kg/m² (adjusted HR 0.286, 95% CI 0.087–0.941; p = 0.039).
Elevated body fat percentage independently predicted reduced mortality after adjusting for tumour stage and metastatic status (adjusted HR 0.289, 95% CI 0.087–0.963; p = 0.036).
Neither baseline BMI nor body fat percentage was significantly associated with the incidence of confirmed immune-related adverse events.

Cite This Study

Morell et al. (2026) studied this question.

synapsesocial.com/papers/6a97e28dc562ede874ec6ae9 https://doi.org/10.3390/jpm16090457

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark